EP1555020A3 - Dérivés benzimidazoles utilisés en tant que modulateurs d'ige - Google Patents

Dérivés benzimidazoles utilisés en tant que modulateurs d'ige Download PDF

Info

Publication number
EP1555020A3
EP1555020A3 EP05075246A EP05075246A EP1555020A3 EP 1555020 A3 EP1555020 A3 EP 1555020A3 EP 05075246 A EP05075246 A EP 05075246A EP 05075246 A EP05075246 A EP 05075246A EP 1555020 A3 EP1555020 A3 EP 1555020A3
Authority
EP
European Patent Office
Prior art keywords
ige
modulators
benzimidazole derivatives
allergens
allergy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05075246A
Other languages
German (de)
English (en)
Other versions
EP1555020A2 (fr
Inventor
Jagadish Sircar
Michael G. Campbell
Mark L. Richards
Michael W. Major
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avanir Pharmaceuticals Inc
Original Assignee
Avanir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals Inc filed Critical Avanir Pharmaceuticals Inc
Priority claimed from EP99924442A external-priority patent/EP1077700B1/fr
Publication of EP1555020A2 publication Critical patent/EP1555020A2/fr
Publication of EP1555020A3 publication Critical patent/EP1555020A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP05075246A 1998-05-22 1999-05-21 Dérivés benzimidazoles utilisés en tant que modulateurs d'ige Withdrawn EP1555020A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8649498P 1998-05-22 1998-05-22
US86494P 1998-05-22
EP99924442A EP1077700B1 (fr) 1998-05-22 1999-05-21 DERIVES BENZIMIDAZOLES UTILISES EN TANT QUE MODULATEURS D'IgE

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP99924442A Division EP1077700B1 (fr) 1998-05-22 1999-05-21 DERIVES BENZIMIDAZOLES UTILISES EN TANT QUE MODULATEURS D'IgE

Publications (2)

Publication Number Publication Date
EP1555020A2 EP1555020A2 (fr) 2005-07-20
EP1555020A3 true EP1555020A3 (fr) 2006-05-24

Family

ID=34621596

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05075246A Withdrawn EP1555020A3 (fr) 1998-05-22 1999-05-21 Dérivés benzimidazoles utilisés en tant que modulateurs d'ige

Country Status (1)

Country Link
EP (1) EP1555020A3 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0719765A2 (fr) * 1994-12-27 1996-07-03 Mitsui Toatsu Chemicals, Inc. Dérivés de phénylbenzimidazole

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0719765A2 (fr) * 1994-12-27 1996-07-03 Mitsui Toatsu Chemicals, Inc. Dérivés de phénylbenzimidazole

Also Published As

Publication number Publication date
EP1555020A2 (fr) 2005-07-20

Similar Documents

Publication Publication Date Title
MXPA00011422A (es) Derivados de bencimidazol como moduladores de ige.
WO2002060900A3 (fr) Antagonistes vis-a-vis de la fonction mcp-1 et procedes d'utilisation
EP0780128A3 (fr) Compositions contenant des lipoprotéines et des dérivés d'amides de l'acide crotonique
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
TNSN02021A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
EP2322201A3 (fr) Les compositions et les methodes pour le traitement de maladies liées immunisées
WO2003053359A3 (fr) 1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d'affections
EP1864975A3 (fr) Dérivés de nicotinamide utiles comme inhibiteurs de P38
EP2769715A3 (fr) Procédés pour le traitement de troubles auto-immuns et réactifs associés
EP2289492A3 (fr) Compositions de clorhydrate de naltrexone
EP2182006A3 (fr) Compositions et procédés pour le traitement de maladies liées au système immunitaire
ATE273304T1 (de) (s)-4-amino-5-chloro-2-methoxy-n-(1-(1-(2- tetrahydrofuryl-carbonyl)-4-piperidinylmethyl)- - piperidinyl)benzamid zur behandlung von magen- darmbewegungskrankheiten
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
CA2415354A1 (fr) Derives phospholipides de l'acide valproique et leurs melanges
CA2171446A1 (fr) Antagonistes du recepteur de la bradykinine pseudo-peptidique et non peptidique
EP1736470A3 (fr) Dérivés de pyrimidine comme modulateurs du récepteur cannabinoide CB2
ATE267816T1 (de) Tan-1057 derivate
NO983860L (no) Nye triazolopuriner, fremgangsmÕte for deres fremstilling og deres anvendelse som legemidler
EP1555020A3 (fr) Dérivés benzimidazoles utilisés en tant que modulateurs d'ige
DK1051404T3 (da) Substituerede phenyluraciler med herbicid virkning
ITMI20021277A1 (it) Perfluoropolieteri comprendenti unita' ripetitive ottenute dall'ossidazione di perfluorodiossoli
SE9901273D0 (sv) Novel compounds
ATE236159T1 (de) Neuartige bispidin-derivate, die sich zur behandlung von herzrhythmusstörungen eignen
EP1595879A3 (fr) Composés de benzimidazole substitués par un alkoxy, préparations pharmaceutiques contenant ces derniers, et procédés d'utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1077700

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20061122

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MAJOR, MICHAEL W.,

Inventor name: RICHARDS, MARK L.,

Inventor name: CAMPBELL, MICHAEL G.,

Inventor name: SIRCAR, JAGADISH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080221